A Preliminary Study of Serum Apelin Levels in Patients with Head and Neck Cancer

Basit Öğe Kaydı
dc.contributor.authorAktan, Meryem
dc.contributor.authorOzmen, Hilal Kiziltunc
dc.date.accessioned2024-02-23T14:41:04Z
dc.date.available2024-02-23T14:41:04Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractObjective: Treatment planning is primarily based on the tumor node metastasis (TNM) staging system for head and neck cancer (HNC). However, TNM does not give sufficient information about biological aggressiveness, treatment response, and prognosis. New molecular markers are needed for individualized cancer treatment. Apelin is a bioactive peptide and an endogenous ligand for the G protein-coupled receptor (APJ). Its expression is induced under hypoxic conditions. Apelin and its receptor APJ are important factors in physiological angiogenesis and may be novel targets for anti-angiogenic tumor therapies. This preliminary study aimed to investigate whether there was a difference in serum apelin levels between patients with HNC and control group and also to compare the serum apelin levels before and after radiotherapy. Materials and Methods: Twenty-two patients with HNC (patient group) and 30 healthy individuals (control group) were included in the study. In the patient group, blood samples were collected before and after radiotherapy. Serum apelin-36 levels were measured by enzyme-linked immunosorbent assay. Results: Serum apelin-36 levels were significantly higher in patients with HNC than in the control group (p<0.001). Coverage of the measured apelin-36 levels showed a significant decrease after radiotherapy according to the levels before radiotherapy. There was no statistically significant difference between the groups (p>0.05). Conclusion: Apelin may be a potential therapeutic target and a novel biomarker. Additional studies are needed to reveal the relationships between serum apelin and radiotherapy in solid human tumors.en_US
dc.identifier.doi10.5152/eurasianjmed.2018.18411
dc.identifier.endpage59en_US
dc.identifier.issn1308-8734
dc.identifier.issn1308-8742
dc.identifier.issue1en_US
dc.identifier.pmid30911258en_US
dc.identifier.scopus2-s2.0-85063516408en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage57en_US
dc.identifier.urihttps://doi.org/10.5152/eurasianjmed.2018.18411
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16698
dc.identifier.volume51en_US
dc.identifier.wosWOS:000462160900013en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofEurasian Journal Of Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectApelinen_US
dc.subjectRadiotherapyen_US
dc.subjectHead And Neck Canceren_US
dc.titleA Preliminary Study of Serum Apelin Levels in Patients with Head and Neck Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu